189 related articles for article (PubMed ID: 35730568)
1. IL-4 prevents adenosine-mediated immunoregulation by inhibiting CD39 expression.
Fang F; Cao W; Mu Y; Okuyama H; Li L; Qiu J; Weyand CM; Goronzy JJ
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35730568
[TBL] [Abstract][Full Text] [Related]
2. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
3. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
[TBL] [Abstract][Full Text] [Related]
4. CD39-mediated ATP-adenosine signalling promotes hepatic stellate cell activation and alcoholic liver disease.
Shuai C; Xia GQ; Yuan F; Wang S; Lv XW
Eur J Pharmacol; 2021 Aug; 905():174198. PubMed ID: 34033815
[TBL] [Abstract][Full Text] [Related]
5. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
[TBL] [Abstract][Full Text] [Related]
6. Purinergic dysregulation in pulmonary hypertension.
Visovatti SH; Hyman MC; Goonewardena SN; Anyanwu AC; Kanthi Y; Robichaud P; Wang J; Petrovic-Djergovic D; Rattan R; Burant CF; Pinsky DJ
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H286-98. PubMed ID: 27208163
[TBL] [Abstract][Full Text] [Related]
7. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
8. Deletion of cd39/entpd1 results in hepatic insulin resistance.
Enjyoji K; Kotani K; Thukral C; Blumel B; Sun X; Wu Y; Imai M; Friedman D; Csizmadia E; Bleibel W; Kahn BB; Robson SC
Diabetes; 2008 Sep; 57(9):2311-20. PubMed ID: 18567823
[TBL] [Abstract][Full Text] [Related]
9. IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells.
Noble A; Mehta H; Lovell A; Papaioannou E; Fairbanks L
Eur J Immunol; 2016 Jun; 46(6):1438-48. PubMed ID: 26990545
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of ecto-nucleoside triphosphate diphosphohydrolase 1 (CD39) involved in regulating extracellular ATP-mediated innate immune responses in Japanese flounder (Paralichthys olivaceus).
Li S; Chen X; Wang N; Li J; Feng Y; Sun J
Mol Immunol; 2019 Aug; 112():10-21. PubMed ID: 31075558
[TBL] [Abstract][Full Text] [Related]
11. Elevated CD39+T-Regulatory Cells and Reduced Levels of Adenosine Indicate a Role for Tolerogenic Signals in the Progression from Moderate to Severe COVID-19.
Elsaghir A; El-Sabaa EMW; Zahran AM; Mandour SA; Salama EH; Aboulfotuh S; El-Morshedy RM; Tocci S; Mandour AM; Ali WE; Abdel-Wahid L; Sayed IM; El-Mokhtar MA
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139439
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
13. Ecto-NTPDase CD39 is a negative checkpoint that inhibits follicular helper cell generation.
Cao W; Fang F; Gould T; Li X; Kim C; Gustafson C; Lambert S; Weyand CM; Goronzy JJ
J Clin Invest; 2020 Jul; 130(7):3422-3436. PubMed ID: 32452837
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the expression and function of the P2X7 receptor and ART1 in human regulatory T-cell subsets.
Cortés-Garcia JD; López-López C; Cortez-Espinosa N; García-Hernández MH; Guzmán-Flores JM; Layseca-Espinosa E; Portales-Cervantes L; Portales-Pérez DP
Immunobiology; 2016 Jan; 221(1):84-93. PubMed ID: 26307000
[TBL] [Abstract][Full Text] [Related]
15. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.
Hilchey SP; Kobie JJ; Cochran MR; Secor-Socha S; Wang JC; Hyrien O; Burack WR; Mosmann TR; Quataert SA; Bernstein SH
J Immunol; 2009 Nov; 183(10):6157-66. PubMed ID: 19864600
[TBL] [Abstract][Full Text] [Related]
16. CD39 mediated regulation of Th17-cell effector function is impaired in juvenile autoimmune liver disease.
Liberal R; Grant CR; Ma Y; Csizmadia E; Jiang ZG; Heneghan MA; Yee EU; Mieli-Vergani G; Vergani D; Robson SC; Longhi MS
J Autoimmun; 2016 Aug; 72():102-12. PubMed ID: 27210814
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.
Li XY; Moesta AK; Xiao C; Nakamura K; Casey M; Zhang H; Madore J; Lepletier A; Aguilera AR; Sundarrajan A; Jacoberger-Foissac C; Wong C; Dela Cruz T; Welch M; Lerner AG; Spatola BN; Soros VB; Corbin J; Anderson AC; Effern M; Hölzel M; Robson SC; Johnston RL; Waddell N; Smith C; Bald T; Geetha N; Beers C; Teng MWL; Smyth MJ
Cancer Discov; 2019 Dec; 9(12):1754-1773. PubMed ID: 31699796
[TBL] [Abstract][Full Text] [Related]
18. Targeted deletion of ectonucleoside triphosphate diphosphohydrolase 1/CD39 leads to desensitization of pre- and postsynaptic purinergic P2 receptors.
Schaefer U; Machida T; Broekman MJ; Marcus AJ; Levi R
J Pharmacol Exp Ther; 2007 Sep; 322(3):1269-77. PubMed ID: 17565006
[TBL] [Abstract][Full Text] [Related]
19. The abnormal function of CD39
Lu Y; Cheng L; Li F; Ji L; Shao X; Wu B; Zhan Y; Liu C; Min Z; Ke Y; Sun L; Chen H; Cheng Y
Ann Hematol; 2019 Aug; 98(8):1845-1854. PubMed ID: 31154474
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
